ACAD vs LBRX
ACAD: Acadia Pharmaceuticals is a biopharmaceutical company specializing in developing and commercializing innovative treatments for central nervous system and rare disease indications. LBRX: A biopharmaceutical company developing LB-102, a novel, late-stage benzamide antipsychotic candidate targeting schizophrenia and mood disorders.
Side-by-side fundamentals
| Metric | ACAD | LBRX | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $20.19 | $39.23 | |
| Market cap | $3.5B | $1.3B | |
| P/E as of 2026-10-21 | 9.05 | n/a | |
| Net margin FY2025, SEC XBRL | +36.5% | n/a | |
| Gross margin FY2025, SEC XBRL | +91.7% | n/a | |
| Operating margin FY2025, SEC XBRL | +9.8% | n/a | |
| ROE FY2025, SEC XBRL | +31.9% | -8.4% | ACAD higher |
| ROA FY2025, SEC XBRL | +25.0% | -8.1% | ACAD higher |
| Revenue growth (YoY) FY2025, SEC XBRL | +11.9% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +27.5% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.85 | 0.56 | |
| 1-year return as of 2026-10-21 close | -5.1% | +145.2% | LBRX higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.